¹ú²ú³ÉÈ˾«Æ·°×½¬¾Ã¾Ã69

This week we showcase publications from leading journals across the scientific fields. In a way, this mirrors the diversity of specialists in clinical settings and beyond who collaborate to treat addiction.

Prevalence of Cannabis Use Disorder and Reasons for Use Among Adults.

Examining sociodemographic correlates of opioid use, misuse, and use disorders in the All of Us Research Program

Marijuana and hallucinogen use, binge drinking reached historic highs among adults 35 to 50

Perceptions of Safety of Daily Cannabis vs Tobacco Smoking and Secondhand Smoke Exposure, 2017-2021

The Future of Addiction Treatment Lies in Narrowing the Treatment Gap

In the time of the worst overdose crisis in American history, those of us who work in the field of addiction medicine have the responsibility of bringing treatment to where patients with addiction are. The addiction treatment gap refers to the approximately 94% of people with one or more DSM-5 defined substance use disorders (SUDs) who did not receive any addiction treatment (according to the SAMHSA’s National Survey on Drug Use and Health (NSDUH) conducted in 2021).

¹ú²ú³ÉÈ˾«Æ·°×½¬¾Ã¾Ã69 Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder

Guest Editorial by David A. Gorelick, MD, PhD, DLFAPA, F¹ú²ú³ÉÈ˾«Æ·°×½¬¾Ã¾Ã69

Cannabis potency, the content of ∆9-tetrahydrocannabinol (THC), usually expressed as the percentage of dry weight, has increased substantially worldwide over the past four decades [1]. This higher potency poses a risk of increased harms because of evidence of a positive association between cannabis potency and adverse psychiatric effects from long-term cannabis use. This article reviews the evidence for this association.